The specialized microenvironments of lymphoid tissue affect immune cell function and progression of disease. However, current animal models are low throughput and a large number of human diseases are difficult to model in animals. Animal models are less amenable to manipulation of tissue niche components, signalling pathways, epigenetics, and genome editing than ex vivo models. On the other hand, conventional 2D cultures lack the physiological relevance to study precise microenvironmental interactions. Thus, artificial tissues are being developed to study these interactions in the context of immune development, function, and disease.
INTRODUCTION
Immune cell function is highly dependent on communication with the surrounding microenvironment. Specialized microenvironments, such as primary lymphoid organs and secondary lymphoid tissues, efficiently inform immune cells to combat pathogens and repair tissue. Individual changes in the surrounding microenvironmental cellular components, soluble signals, extracellular matrix (ECM) composition, and stiffness have been shown to affect immune cell maturation, migration, and function. These interactions are crucial to homeostatic regulation, tolerance, and mounting adaptive immune responses, whereas their dysregulation can lead to the progression of disease and affect ensuing therapeutic responses.
The study of these specialized microenvironments and their individual components have primarily relied on wild type and genetically engineered animal models. However, are low throughput and human lymphoid malignancies are difficult to model in current animal models. Animal models further lack high tunability of cell, matrix, and biochemical composition to grow matched healthy and diseased cell types from human patients to identify biomarkers and more effective treatments. On the other hand, conventional 2D in-vitro models afford needed biological control, but present an oversimplification of the natural microenvironment. To ultimately bridge the gap between the high-throughput, cost-effective nature of in-vitro systems with the physiological relevance of in-vivo models, the creation of artificial tissue models has garnered interest ( Fig. 1 ). Ex vivo tissue models are more amenable to manipulation of surrounding niche components, epigenetic modulation and control over signalling pathways, as well as genome editing than in vivo models. Importantly, ex vivo tissues can be constructed from limited amounts of starting biomaterials, and can recapitulate patientspecific conditions by incorporating other human cell types, such as immune cells.
In particular, immune-based microenvironments, including that of the bone marrow and lymph node, are being developed to effectively culture primary immune cells for a better understanding of immune cell maturation and function. These models are also used to test the efficacy of immunomodulatory agents and inform the development of antibody and cell-based immunotherapeutics. In this review, we explore bone marrow and lymph node models used to correspondingly, study hematopoiesis and germinal center-like biology. We also discuss how these models are being extended to study the progression and therapeutic response of bone marrow and lymph node-based hematological malignancies, including leukemia, multiple myeloma, and lymphoma.
BONE MARROW
For bone marrow models, the primary aim has been to elucidate how the microenvironment facilitates hematopoiesis. The hope is that this understanding will lead to increases in in-vitro expansion yields, engraftment efficiencies, and overall long-term homeostasis of clinically relevant hematopoietic stem cell (HSC) populations for use in HSC transplantation. Additional biomimetic models have been created to evaluate drug toxicity on the hematopoietic system.
Lately, these models have shifted from expanding HSCs in static 2D culture to biomaterial-based 3D cultures to provide greater spatiotemporal control of multiplexed cell, biophysical, and biomolecular signals reminiscent of the native environment. In the native microenvironment, putative quiescent HSCs localize close to the endosteal bone surface, whereas actively cycling HSCs are found near the sinusoidal endothelium. Although these niches are close in proximity and may even overlap, decreasing gradients of calcium and matrix stiffness along with increases in C-X-C Motif Chemokine Ligand 12 (CXCL12) expression have been found between them. The endosteam is also associated with high levels of fibronectin as opposed to high levels of laminin in the perivascular space [1, 2] .
In modeling these differences, initial 3D culture studies have primarily focused on comparing material composition, mechanical properties, architecture, topology, and overall culture conditions for increased yields of HSC ex vivo [3] [4] [5] [6] [7] [8] [9] . Several elegant reviews have summarized the findings for each model and future directions to better understand the native endosteal or perivascular niche [2, 10] .
To better design systems for increasing HSC yield, Choi and Harley studied the effect of marrow-inspired matrix cues and biophysical signals on HSC fate decisions [11 && ]. They coated polyacrylamide surfaces with either type I collagen, laminin, or fibronectin of varying stiffness. Within 24 h, matrix ligand type and stiffness regulated HSC morphology, proliferation, and myeloid lineage specification based on integrin engagement and the myosin II activation processes. In particular, high fibronectin content with greater stiffness maintained HSC stemness, most likely via a 5 b 1 integrin activation, conversely, high laminin content promoted myeloid specification, especially that of the erythrocyte lineage when high intracellular tension was induced. These findings mirror the biophysical properties and expected biological outcomes present in native endosteal and perivascular niche. They also dictate the explicit role matrix ligands play in regulating HSC fate [11 && ]. Based on this findings, concominant presentation of fibronectin and scheduled biophysical signals may increase in vitro HSC expansion yields. Specifically, photolabile and photoactivable crosslinkers could be used to either soften or harden specific matrix locales. Multiplexed biochemical gradients, including that of CXCL12, can also be added with the use of dynamic flow-based approaches, such as microfluidic devices. Further incorporation of downstream single-cell analysis tools could be used to decode the nuances of heterogeneous HSC responses in both regulation and function [12, 13] .
KEY POINTS
Bone marrow and lymph node platforms have been developed to study microenvironmental interactions in hematopoiesis and germinal center-like biology.
Dysregulation of these interactions have been noted and modeled for leukemia, multiple myeloma, and lymphoma.
Advances in biomaterials, genome editing, and singlecell analysis technologies will further improve the reproducibility and functionality of these models.
Instead of recreating the entire niche, researchers have also focused on modeling certain features of the bone marrow niche for the clinical expansion of HSC-derived blood and immune cells. Di Buduo et al. modeled the walls of venous sinusoids for platelet formation [14 && ]. They created programmable silk scaffolds that supported endothelial cells and megakaryocyte growth on opposite sites, and then modulated the surface topography, stiffness, ECM composition, and external shear forces to form millions of functional human platelets [14 && ]. This elaborate system not only enables the study of megakaryopoiesis but also allows for the expansion of clinically translatable human platelets.
Coincident efforts have also similarly extended these models to create biomimetic niche-like analogs to evaluate the drug toxicity on HSC populations. Torisawa et al. [15] created a 'bone-marrowon-chip' platform by first implanting a collagen scaffold infused with demineralized bone powder, Bone Morphogenic Proteins 2 and 4 into mice to form bone in vivo, and then harvesting the bone and perfusing it with a microfluidic device for long-term culture. The ensuing engineered bone marrow Tissue models to study and hematological malignancies Shah and Singh displayed radiation injury responses similar to those found in native marrow. They also recently extended this platform to more closely model hematopoiesis by maintaining HSCs and forming blood cells for 2 weeks in culture. This platform responded positively to possible radiation countermeasure drugs, granulocyte-colony stimulating factor, or bactericidal/permeability-increasing protein, postradiation injury [16 & ]. However, to allow for translation of these preclinical findings from bench to bedside, differences between mice and human in terms of morphological and functional niche features as well as overall cellular biology must be considered. Decellularization approaches combined with the use of human-induced pluripotent stem cells can be a step forward into preparing this platform for clinical translation.
LYMPH NODES
The microenvironment of lymph nodes consists of spatially patterned ECM and stromal matrix of follicular dendritic and reticular cells to enable the migration of B, T, and dendritic cells [17] . These dynamic migration processes facilitate communication between the outer sampling, B-cell activation, and T-cell activation zones during adaptive immune responses [18] . These migration processes, especially that of T cells, have previously been studied using 3D scaffolds [19] . More recent models of the secondary lymphoid tissues are focused on understanding germinal center physiology and pathophysiology to inform the creation of antibody-based therapeutics. The germinal centers are highly affected by cellular-microenvironmental interactions and the germinal center B cells must be rescued by antiapoptotic signals, further limiting their expansion ex vivo with 2D cultures. Slight improvements in 2D culture were made when Nojima et al. [20] cocultured naïve B cells with '40LB' cells, their genetically modified stromal cell line engineered to present CD40 Ligand and B cell activating factor. Although activated B cells were reportedly formed, memory B-cell formation was dependent on transplantation into mice.
Our group has, therefore, aimed to create germinal centers ex vivo by emulating the lymphoid microenvironment. Purwada et al. first engineered gelatin hydrogels reinforced with polyionic silicate nanoparticles to encapsulate murine naïve B cells and 40LB cells in the presence of exogenous interleukin-4. The silicate nanoparticles enabled us to mirror the stiffness, porosity, and architecture of native lymphoid tissue, whereas Arg-Gly-Asp (RGD) motifs present in the gelatin also mimicked native ECM. By imitating the lymphoid microenvironment, these 'immune organoids' produced 100 fold increase in germinal center B cells when compared to a modest 10-20-fold development in 2D cultures and induced antibody class switching. They also found that proliferation of germinal center B cells were dependent on the interaction between B-cell integrin a v b 3 and RGD-motifs in the gelatin [ This mechanistic understanding will instruct future biomaterial model design to produce long-lived, high-affinity activated B cells and antibody-based therapeutics.
BONE MARROW MALIGNANCIES
Crosstalk between the microenvironment and malignant cells often regulates the initiation, progression, and ensuing therapeutic response of disease. The pathophysiology is often tied to dysregulation of microenvironmental interactions. Therefore, understanding and modeling these changes can significantly inform development of personalized, microenvironment-based therapies and help overcome environment-mediated and acquired resistance to current therapeutics.
Within the bone marrow niche, there is particular interest in modeling leukemia and multiple myeloma. In the case of acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), and chronic myeloid leukemia (CLL), changes in interactions with the bone marrow stromal microenvironment has been shown to promote leukemic cell survival and affect therapeutic response [24] . These interactions have also been implicated in immunosuppression and reduced T-cell activation, thereby minimizing the efficacy of T-cell redirection therapies [25] . Therapeutics can also alter the stromal microenvironment after treatment, potentially changing the progression of disease and mediating environment-mediated resistance [26] . Microenvironment-induced increased vascular permeability and PIM kinase expression have also been noted in AML and chronic lymphocytic leukemia, respectively [27] [28] [29] . Recently, a 3D microfluidic ALL cell culture platform was created to study how changes in the microenvironment affected drug response. Primary human bone marrow stromal cells, leukemic cells, and osteoblasts were encapsulated in a 3D collagen gel and then exposed to physiological flow. 2D-static, 3D-static, and 3D-flow cultures were exposed to cytarabine, an antimetabolite chemotherapeutic agent. Decreased sensitivity in the 3D models alluded to the microenvironment's protective role for tumor cell survival [30 & ].
For multiple myeloma, interactions with the microenvironment are tied to disease progression and relapse because of its prosurvival effect on reservoirs of residual multiple myeloma cells. Distinguishing characteristics of the prosurvival microenvironment, including cell membrane protein junctional adhesion molecule-A, high expression of transmembrane receptor roundabout 1, and absolute lymphocyte/monocyte ratio, can serve as clinical biomarkers and potential therapeutic targets [31] [32] [33] . To identify additional potential targets in multiple myeloma cells induced by the microenvironment, Meads et al. recently conducted activitybased protein profiling along with a high-throughput protein kinase inhibitor screen on multiple myeloma patient specimens [34] . This screen resulted in eight protein kinase inhibitors that showed significant activity, and it displayed how this method can pinpoint changes in tumor cells in situ to help overcome therapy-induced resistance [34] . Microenvironmental changes in multiple myeloma have also been recently studied using 3D scaffolds derived from the bone marrow of multiple myeloma patients. Fibrinogen present in the plasma of the supernatant was crosslinked with calcium and encapsulated the patient's multiple myeloma cells, stromal cells, and endothelial cells. These models mimicked native multiple myeloma growth, interactions with the microenvironment, and biochemical gradients, including that of oxygen and drug availability. They also induced greater drug resistance in comparison to conventional 2D and commercial 3D cultures. Therefore, the multiple myeloma culture models can increase our understanding of tumor pathophysiology and have the potential to inform personalized therapeutic plans [35 && ].
LYMPH NODE MALIGNANCIES
Models of the sub-anatomical parts of lymph node have been extended to elucidate the relationship between the microenvironment and lymphoma, which are the lymphoproliferative cancer of B and T cells. Initial lymphoma cellular aggregates alluded to the importance of 3D culture as the expression level of 7000 genes and therapeutic response to chemo and antibody-based therapeutics differed between 3D and 2D cultures [36] [37] [38] . In comparison to 2D cultures, virally infected lymphoma aggregates grown in 3D microwells also displayed a larger viral genome copy number and higher rate of lytic reactivation. [39] Although these multicellular aggregates are informative, they do not account for the effect of cell-cell interactions, cellular-ECM interactions, and tumor heterogeneity.
Mannino et al. recently concentrated on cellcell communication between endothelial and lymphoma cells [40] . They created a 'lymphomaon-chip' model by encapsulating tumor cells in a hyaluronic acid-based hydrogel that was traversed by a perfusable, fully endothelized microchannel. Tumor cells increased endothelial cell permeability and responded to targeting colony stimulating factor 1 receptor antibodies with expected macrophage death. This chip also enabled cells to be extracted for mechanistic studies. With additional modifications, distinct microenvironments can be connected to understand the downstream effects of tumor cells and therapeutics [40] .
The chip is a promising initial step to inform drug delivery within tumor vasculature. However, for clinical translation, intratumor changes within matrix density, composition, and even stiffness and their effect on vascular outgrowth, branching, and integrity must be modeled and considered [41] .
Within cellular-ECM interactions, integrinmediated crosstalk between lymphoma cells and the ECM has been shown to affect survival and chemoresistance [42, 43] . Inhibition of integrin a v b 3 , in particular, decreased nuclear factor kappa-lightchain-enhancer of activated B cells-mediated Vascular endothelial growth factor A and VEGFB upregulation and induced lymphoma cell death in vitro and in patient-derived xenograft mouse models [43] . To further understand integrin signaling within lymphomas, Tian et al. [44 & ] used the aforementioned integrin ligand-specific polyethylene glycol -MAL system to encapsulate either malignant B or T lymphoma cells with follicular dendritic cells. Through these 'lymphoma organoids', B and T-cell lymphomas were found to have different integrin-signaling requirements for survival. When compared to 2D cultures, these 3D organoids also displayed enhanced proliferation, clustering, and drug resistance to common chemotherapeutics and pabinostat, an epigenetic histone deacetylase inhibitor. In diffuse large B-cell lymphoma cell lines, integrin ligand presentation upregulated B-cell receptor (BCR) expression, plausibly explaining the enhanced survival.
Lymphoma tumors heterogeneity within cell and ECM composition is further complicated by biophysical gradients. Apoorva et al. focused on the heterogeneity of biophysical forces in the tumor microenvironment by using the previously described gelatin system. They found that lymphoma survival, proliferation, drug response, and BCR expression are affected by stiffness in a molecular subtype dependent manner [45 & ]. The changes in drug resistance, drug delivery, and gene expression within these three models seem to better capture the heterogeneity of lymphoma tumors and show potential for uses in drug screening and development.
CONCLUSION
Overall, the creation of 3D has identified key microenvironment interactions in immune function, development, and disease that previously could not be studied in animal models and conventional 2D cultures. Incorporation of tunable and designer biomaterials will improve the reproducibility and functional of these model for additional mechanistic understanding [46] . Future work should consider including patient-derived immune cells to enable formation of an immune synapse. Similarly, the use of genome editing and single-cell analysis tools will also answer questions regarding driver genetic and epigenetic mutations as well as tumor heterogeneity. Continual refinement will enable the identification of potential therapeutic targets and biomarkers to inform the development of antibody and cell-based immunotherapeutics for patientspecific treatment plans.
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